Introducing
Regenerate. Restore. Relieve.
India's first autologous exosome kitIndia's first autologous exosome kit enriched with growth factor concentrate represents a breakthrough in regenerative medicine — combining autologous exosomes with platelet-derived growth factors (GFs) to accelerate healing, reduce inflammation, and restore mobility naturally.
Exosomes — nature's nanocarriers
Exosomes are nanosized "biological messengers" released by cells. Rich in proteins, lipids, and genetic material, they deliver vital healing signals that promote repair and regeneration at the cellular level.
Quantified by sandwich ELISA in the final OrthoGain preparation.
| Growth factor | Concentration | Unit | Primary role |
|---|---|---|---|
| PDGF | 99,443.75 | pg/ml | Fibroblast activity, tendon and ligament repair |
| VEGF | 3,899 | pg/ml | Angiogenesis, nutrient and oxygen delivery |
| bFGF | 2,793 | pg/ml | Cell proliferation, soft-tissue repair |
| TGF-β | 1,732.50 | pg/ml | Collagen synthesis, cartilage and bone remodelling |
| EGF | 550 | pg/ml | Cellular proliferation, wound healing |
ELISA analysis confirms the growth factor content of each OrthoGain preparation — PDGF, VEGF, EGF, TGF-β and bFGF. Consistent biomarker enrichment is what the preparation protocol is designed to deliver, batch to batch. Composition data describes what is in the product, not its clinical effect; see clinical evidence.
The synergy of OrthoGain™. By combining autologous exosomes (loaded with mRNA & proteins) and concentrated growth factors, OrthoGain™ delivers a pioneering regenerative solution for orthopaedics and sports medicine.
Mechanism
OrthoGain is designed to act through direct exosome-mediated cellular communication, with the aim of lower inflammation, better patient comfort and quicker visible results.
From ligament tears, tendon injuries, and fractures.
Without steroid side effects.
Of muscles, cartilage, and bone.
And performance, for athletes and active patients.
No rejection or allergy risk.
Clinical applications
Chairside preparation
Six steps, from venous draw to filtered autologous product.
Head to head
| Parameters | PRP | GFC | EXOS-GFC |
|---|---|---|---|
| Composition | Platelets with plasma | Platelet-derived growth factors | Autologous exosomes + growth factors |
| Mechanism | Indirect GF release | Direct GF delivery | Direct cellular communication + potent regenerative signaling |
| Regenerative capacity | Moderate | Improved | Designed to target inflammation and stimulate regeneration |
| Purity | Contains RBCs/WBCs | Contains cell debris | RBC-free, cell-free, highly purified exosomes |
| Onset of results | 4–6 weeks | 2–3 weeks | 1–2 weeks |
Source: Comparison compiled from the OrthoGain product brochure (OXG-BRC-01-25062026, Rev-01). Onset ranges are indicative and vary by patient, indication and protocol; they are not derived from a head-to-head controlled trial.
Nanoparticle Tracking Analysis (NTA)
Nanoparticle Tracking Analysis is a technique used to measure the size distribution and concentration of nanoparticles, including exosomes. NTA combines the principles of laser light scattering and Brownian motion to provide detailed insight into exosome populations.
2.05e+13 particles/ml
Original exosome concentration.
85.7% of particles between 30–150 nm, with a therapeutic peak at 100 nm.
>98% exosome and growth factor content with negligible impurities. NTA supports batch-to-batch consistency of the preparation.
Source: Nanoparticle Tracking Analysis, [instrument / model] at [testing laboratory, city], report no. [report no.], [test date], n = [n] samples. Full report available to clinicians on request.
Clinical evidence
OrthoGain is characterised analytically. We say so plainly rather than describing the product as clinically proven.
Analytical data — clinical study pending
Orthopaedic study status: [confirm whether an orthopaedic clinical study is registered or planned - supply details, or delete this line]
This page will be updated as clinical data becomes available.
Safety
OrthoGain is prepared from the patient’s own blood at the point of care. Its safety profile follows from that.
Every dose is derived from the patient’s own venous blood. There is no donor-derived, animal-derived or cultured cell material, and therefore no risk of immune rejection or cross-donor transmission.
The kit is sterile and single-use. Tubes, syringes and the filter are discarded after one preparation; nothing is pooled, stored or reused between patients.
OrthoGain contains no corticosteroid and no synthetic drug substance, so the systemic and local effects associated with repeated steroid injection do not apply.
Reactions are those of the venous draw and the injection itself — transient soreness, redness, swelling or minor bruising at the draw or treatment site, typically settling within a few days.
To be prepared and administered by a qualified healthcare professional trained in the protocol, under aseptic technique and, where indicated, image guidance for intra-articular injection.
Refer to the Instructions for Use supplied with the kit for the full list of contraindications, warnings and precautions, including patient selection criteria.
Safety reporting: [adverse-event statement, as of (date) — supply or delete this sentence] Clinicians should report any suspected adverse event to info@orthogain.in.
Send us your details and we will come back with pricing, the full preparation protocol, the assay reports and training options.
What ships
Approved by the Central
Drugs Standard Control Organisation, India.
Downloads
For clinicians and distribution partners. Assay reports and the Instructions for Use are sent on request — use the enquiry form below.
The full product brochure — science, indications, preparation protocol, comparison against PRP and GFC, assay data and kit contents.
Download PDFThe full ELISA growth factor report and the Nanoparticle Tracking Analysis report, for clinicians who want the underlying data behind the figures on this page.
Request the reportsPreparation steps, aseptic technique, contraindications, warnings and precautions. Supplied with every kit and available in advance to clinicians evaluating the product.
Request the IFUGet in touch
For orthopaedic surgeons, sports medicine physicians, hospitals and distribution partners. Tell us about your practice and we will send pricing, the full protocol and training details.
Kamal Encon Industries Limited
6th Floor, Antriksh Bhawan
Kasturba Gandhi Marg, New Delhi – 110001
India
